Pre-Conference Workshop Day
Tuesday, June 28, 2022 | 9AM - 4.45PM
Take a look at what topics and speakers you can look forward to hearing from on our pre-conference workshop day at this year's 4th Longevity Therapeutics Summit.
9AM Welcome Coffee & Registration
Addressing the Key Challenges in Progressing Towards the Clinic in Longevity Therapeutics
In this dynamic and fast-growing field, many successful preclinical trials are unable to make it to the clinic. This evidence-based workshop will explore the greatest challenges in progressing towards the clinic and explore different methods to overcome these challenges.
Another key challenge facing the longevity field sits with the FDA not recognizing aging as an indication. As such, this interactive workshop will provide a platform to discuss how to advance towards regulatory approval, recognize indications in agerelated diseases and develop drugs solely from a longevity perspective.
Join this workshop to be a part of the discussion between leading minds in the longevity field as they:
- Outline the core challenges in moving towards the clinic
- Examine the failures in early-stage trials that are preventing progression towards the clinic
- Work alongside the FDA and large pharma to develop longevity-specific drugs
- Discuss how to select indications specific to aging while also obtaining regulatory approval
Workshop A Leaders:
Chief Translational Sciences Officer
Houston Methodist Academic Institute
12.45PM Networking Refreshment Break
Challenging the Traditional Model for the Hallmarks of Aging
The hallmarks of aging have provided a useful model for aging in the longevity field and have been the inspiration behind many drug development pipelines for agerelated diseases. However, as the longevity field progresses, it is crucial to discuss whether the hallmarks of aging are becoming too restrictive and if recent industry developments have allowed us to move past this highly simplified model of aging.
Join this deep-dive workshop to:
- Discuss which hallmarks of aging are the most popular targets for drug development and why
- Evaluate whether targeting individual hallmarks or a cocktail of hallmarks is most effective in longevity therapeutics
- Recognize that the hallmarks of aging were modelled from oncology and discuss the limitations of this
- Assess whether such a simplified model of aging is helpful or harmful in longevity drug development
Workshop B Leader:
Chief Executive Officer
The Buck Institute for Aging
Co-Founder & Chief Executive Officer
Rubedo Life Sciences